IUCT-Oncopole & Artios join forces to overcome resistance to therapies for familial breast cancer 13 April 2023 | Press release
Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer 9 February 2023 | Press release
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer 10 August 2022 | Press release
Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation 5 April 2022 | Press release
Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair 16 November 2021 | Press release
Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215 28 September 2021 | Press release
Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X 27 July 2021 | Press release
Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications 17 June 2021 | Press release
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies 7 April 2021 | Press release